Today: 19 April 2026
Subscribe
Browse Category

SGX:U11 3 November 2025 - 1 December 2025

Singapore Stock Market Today: STI Extends Rally on December 1, 2025 as REITs and Mid‑Caps Lead the Charge

Singapore Stock Market Today: STI Extends Rally on December 1, 2025 as REITs and Mid‑Caps Lead the Charge

Singapore’s Straits Times Index closed up 0.19% at 4,532.65 on Monday, marking a third straight gain and leaving the benchmark 21% higher than a year ago. Blue-chip financials and property stocks saw modest inflows, while mid- and small-cap shares like MetaOptics and Low Keng Huat jumped about 17%. Q3 GDP grew 4.2% year-on-year, prompting the government to raise its 2025 growth forecast to around 4%.
1 December 2025
··
Singapore Stock Market: STI Rallies on Rate‑Cut Hopes and IPO Buzz (28–29 Nov 2025)

Singapore Stock Market: STI Rallies on Rate‑Cut Hopes and IPO Buzz (28–29 Nov 2025)

Singapore’s Straits Times Index closed up 0.3% at 4,523.96 on Friday, 28 November, near its record high. Gains in SGX and local banks led the advance, while City Developments fell 1%. About 1.2 billion shares worth S$1.2 billion changed hands. Regional markets were mixed, with Hong Kong, South Korea, and Malaysia down, but Japan’s Nikkei up slightly.
29 November 2025
······
Singapore Stocks Outlook: 10 Things to Know Before the SGX Opens on 25 November 2025

Singapore Stocks Outlook: 10 Things to Know Before the SGX Opens on 25 November 2025

Singapore’s Straits Times Index rose 0.6% to 4,496.63 on Monday, staying close to its all-time high after the government nearly doubled its 2025 GDP growth forecast to around 4%. Jardine Matheson jumped 8.7%, while Singapore Exchange fell 1.1%. Turnover reached S$3.2 billion. Investors are watching for follow-through as global markets rebound on hopes of a US Fed rate cut.
24 November 2025
·····
Singapore Stocks Today (Nov 10, 2025): STI dips 0.1% as OCBC sets record; DBS eases ahead of ex‑div, Genting Singapore leads gainers

Singapore Stocks Today (Nov 10, 2025): STI dips 0.1% as OCBC sets record; DBS eases ahead of ex‑div, Genting Singapore leads gainers

The Straits Times Index slipped 0.1% to 4,488.13, lagging regional gains as OCBC hit a record S$18.19 after strong Q3 results. DBS eased ahead of its Nov 13 ex-dividend date, UOB edged lower, and Genting Singapore led blue-chip gainers. ST Engineering fell 1.3% after completing the SPTel divestment. SingPost shares dropped after a 12.8% profit decline; Singtel held steady following its Bharti Airtel stake sale.
10 November 2025
·····
1 2 3 4

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop